Successful book building for private placement in IDEX
Significantly oversubscribed placement.
The private placement of new shares which was resolved on 22 April 2013 received great interest from investors. The book building resulted in more than twice the planned maximum of NOK 22 million. The board has therefore increased the placement amount to NOK 30 million to better accommodate the investors’ demand for IDEX shares.
The board has resolved to issue 18,771,250 shares at a subscription price of NOK 1.60 per share, thereby raising NOK 30 million new equity and liquidity before expenses.
The issue of the shares will be subject to resolution at IDEX’s annual general meeting on 16 May 2013. Significant shareholders have confirmed that they will support the resolution.
Following the completion of the transaction, the company’s share capital will be NOK 49,342,602 divided into 328,950,680 registered shares at NOK 0.15.
23 April 2013
Ralph W. Bernstein, CEO, +47 9305 9303, firstname.lastname@example.org
Inge Berge, Business development and investor relations, +47 9326 8836, email@example.com
About IDEX ASA
IDEX ASA specialises in fingerprint imaging and recognition technology. IDEX’s vision is to ensure scheme and chip design. Combined with core software solutions for imaging and authentication, the SmartFinger technology enables on-device enrollment, template storage and verification within the very same module. SmartFinger solutions can be seamlessly integrated into a variety of embedded applications such as mobile phones, one-time password devices, Smartcards, payment and ID cards, payment terminals, access control devices and biometric security and login tokens.
IDEX ASA (ticker IDEX) is a Norwegian public company listed at the Oslo Axess marketplace on the Oslo Børs (Oslo stock exchange). For more information, please visit www.idexbiometrics.com or contact IDEX at firstname.lastname@example.org
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.